


3

Title: ANTIBODY AGAINST FIBROBLAST GROWTH FACTOR-23  
Inventors: Yuji YAMAZAKI, *et al.* Dkt. No. 081356-0218  
Appl. No.: 10/500,296 SABE/YT/vlw/bhc (7/12/06)

- Amendment (10 pgs.);
- Amendment Transmittal with Petition for Extension of Time (2 pgs.);
- Exhibit A – pages 58-62 of the Encyclopedia of Molecular Biology (7 pgs.);
- Certified Translation of Japanese Patent Application No. 262020/2002 (156 pgs.);
- Certified Translation of Japanese Patent Application No. 401689/2001 (128 pgs.);
- and
- Credit Card Payment Form for \$1,620.00 (1 pg.).

Due Date: July 13, 2006  
Date Filed: July 12, 2006  
Transaction Code: PUZJAA  
PTO Log No.: 18162

Attorney Initials: SABE/YT  
Insp. By: 10/11/06



LB<sup>NC</sup>

10/500296

MODIFIED PTO/SB/08 (08-00)

Approved for filing through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Application Number</b>	Unassigned
Date Submitted: June 28, 2004		<b>Filing Date</b>	Concurrently Herewith
(use as many sheets as necessary)		<b>First Named Inventor</b>	Yuji YAMAZAKI
		<b>Group Art Unit</b>	Not yet assigned
		<b>Examiner Name</b>	Not yet assigned
<b>Sheet</b>	1 of 1	<b>Attorney Docket Number</b>	081356-0218

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
<i>JK</i>	A1		WO 02/076467		Genzyme Corporation	3/22/2002		
<i>I</i>	A2		WO 01/66595		Chiron Corporation & Kyoto University	3/7/2001		
<i>JK</i>	A3		WO 01/66596		Chiron Corporation & Kyoto University	3/7/2001		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>	
JK	A4	International Search Report		
	A5	Takashi SHIMADA et al., "Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia", Proc. Natl. Acad. Sci., USA, 5/22/2001, Vol. 98, Issue 11, pp. 6500-6505.		
	A6	Yuji YAMAZAKI et al., "Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia", The Journal of Clinical Endocrinology & Metabolism, (11/2002), Vol. 87, No. 11, pp. 4957-4966.		
	A7	Yuji YAMAZAKI et al, "Detection of Circulating FGF-23 by Monoclonal Antibodies Against Recombinant Human FGF-23", Journal of the American Society of Nephrology, (9/2002), Vol. 13, (Program and Abstract Issue), pg. 499A.		
	A8	Takashi SHIMADA et al, "FGF-23 Is a Novel Humoral Factor Regulating Vitamin D Metabolism", Journal of the American Society of Nephrology, (9/2002), Vol. 13, (Program & Abstract Issue), pg. 28A.		
	A9	Takashi SHIMADA et al., "Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo", Endocrinology, (8/2002), Vol. 143, No. 8 pp. 3179-3182.		
	A10	-Yuji YAMAZAKI et al, "Development of the ELISA System Using Monoclonal Antibodies against FGF-23 and Demonstration of Increased Plasma Concentration of FGF-23 in Tumor-Induced Osteomalacia", ENDO, 2002, The Endocrine Society's 84 <sup>th</sup> Annual Meeting, Program & Abstract, pg. 66.		
JK	A11	-Y. YAMAZAKI et al., "FGF-23 Protein is Present in Normal Plasma and Is Increased in Patients with Tumor-Induced Osteomalacia", (9/2002), The Journal of Bone and Mineral Research, Vol. 17, suppl. 1, pg. 159.		

<b>Examiner Signature</b>	<i>[Signature]</i>	<b>Date Considered</b>	1/3/06
-------------------------------	--------------------	----------------------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.